Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) was submitted on August 2, 2021, for the month of August 2021. The report serves as a notification to the market in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R regarding the company's total voting rights and capital structure.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a capital disclosure notice.
| Metric | Value as of July 31, 2021 |
|---|---|
| Issued Share Capital | 5,386,920,872 Ordinary Shares (25 pence each) |
| Treasury Shares | 355,205,950 Ordinary Shares |
| Total Voting Rights | 5,031,714,922 |
Material Changes
The filing does not contain comparative data against prior periods or discuss material changes in financial performance. It solely establishes the denominator for shareholder interest calculations under FCA rules.
Guidance, Outlook, and Risks
The document contains no management commentary, future guidance, risk factors, contingencies, or unusual items. Its sole purpose is to inform shareholders of the total number of voting rights to assist in determining notification thresholds for changes in interest.
Investor Verification Checklist
- Verify the total number of voting rights (5,031,714,922) for calculating disclosure thresholds under FCA rules.
- Confirm the number of shares held in Treasury (355,205,950) to understand the difference between issued capital and voting rights.
- Note that this filing does not contain financial results; refer to Form 20-F or quarterly reports for financial metrics.